FG

Francisco Gimenez

Principal at 8VC

San Francisco, California

Overview 

Francisco Gimenez is a Partner at 8VC in San Francisco, California, with a PhD from Stanford University and a background in bioinformatics and machine learning. He has served on the board of directors for multiple companies and has made strategic investments in various successful ventures such as Latus Bio and Unlearn.AI. Gimenez's career highlights include leading investments in companies like Flywheel.io and Serotiny, while also contributing his expertise to the boards of directors at Cellanome, Appia Bio, and other prominent organizations in the biotech and AI sectors.

Work Experience 

  • Partner

    2020 - Current

  • Principal

    2016

    Healthcare and Biotech investing in Seed and Series A stage companies

  • Resident Data Scientist

    2016 - 2016

    * Building community of data scientists within bay area * Academic outreach for data science recruitment * Help portfolio companies develop data science strategy * Prototype/debug/deploy data products for startups

8VC transform the technology infrastructure behind many industries.

  • Board Observer

    2021

Cellanome engages in cutting-edge synthetic biology and informatics methods through its multi-omics platform.

Raised $213,714,701.00 from PremjiInvest.

  • Board Observer

    2021

Cellino is building a scalable, automated biomanufacturing system for potentially curative personalized cell therapies.

Raised $122,500,002.00 from Advanced Research Projects Agency for Health.

  • Director Board of Directors

    2021

Appia Bio is a biotechnology company that focuses on the research and development of off-the-shelf allogeneic cell therapies.

Raised $52,000,000.00 from 8VC, Sherpa Healthcare Partners, Two Sigma Ventures, Freeflow Ventures, WPSS.bio and Bossa Invest.

  • Director Board Of Directors

    2021

Flywheel.io is a data management and analysis platform built specifically for scientists and the researcher's workflow.

Raised $105,289,919.00 from iSelect Fund, Novalis LifeSciences, Key Fund, Beringea, 8VC, Gundersen Health System, Seraph Group, Great North Ventures, Intuitive Ventures and Invenshure.

  • Director Board Of Directors

    2020

Unlearn.AI combines AI, digital twins, and novel statistical methods to enable smaller, more efficient clinical trials.

Raised $134,850,000.00 from Wittington Ventures, Radical Ventures, DCVC Bio, DCVC, 8VC, Insight Partners, EPIC Ventures, Mubadala Capital, Necessary Ventures and Altimeter Capital.

  • Director Board Of Directors

    2019

BigHat Biosciences is a protein therapeutics company that develops an antibody design platform guided by artificial intelligence.

Raised $99,302,511.00 from Gaingels, 8VC, Andreessen Horowitz, Amgen Ventures, Bristol-Myers Squibb, Quadrille Capital, GRIDS Capital, AME Cloud Ventures and Section 32.

  • Director Board Of Directors

    2019

    Mantra is developing engineered exosomes for delivery of gene therapy machinery and small molecules. The company is working to produce exosomes with combinations of surface-associated targeting moieties that lead to highly selective uptake in particular tissue and cell types of interest. Their efforts have yielded dramatic reductions in liver concentrations with corresponding increases in delivery levels to specific tissues. They are leveraging these results to generate new formulations of drugs otherwise demonstrating unacceptable toxicity levels when administered systemically.

Mantra Bio is the creator of REVEAL, an exosome engineering platform combining computational biology and lab automation.

Raised $34,000,000.00 from Samsung Securities, Illumina, BoxGroup, Allen & Company, 8VC, Viking Global Investors, Viking Global Investors, Allen & Company, 8VC and BoxGroup.

  • Director Board of Directors

    2019

Sirona Medical develops software solutions for healthcare providers that support patient care and clinical workflows.

Raised $104,500,000.00 from Avidity Partners, GreatPoint Ventures and 8VC.

  • Director Board of Directors

    2019

Cambium develops biomaterials for applications across defense, space, aerospace, and renewable energy.

Raised $27,012,877.00 from 8VC, Kern Venture Group, MVP Ventures, Gaingels, Veteran Ventures Capital, Marlinspike Capital, Vertical Capital Advisors and GSBackers.

Articles About Francisco

Relevant Websites